Deconstructing Myogen's market cap

Article Abstract:

Myogen, a biopharmaceutical company in Westminster, Colorado, focusing on cardiovascular diseases, was found to be the best performing stock in 2005. Enoximone, a phosphosiesterase 3 inhibitor used to treat chronic heart failure, darusentan, a selective endothelin receptor antagonist used to treat treatment-resistant hypertension, and embrisentan, an endothelin receptor antagonist developed to treat pulmonary arterial hypertension (PAH), are three main products of Myogen that are under clinical trial.

Market share, Securities issued, listed, Securities, Company securities, Company market share

---

Are small biotechs still underselling themselves?

Article Abstract:

The future of a small biotech company, AtheroGenics, could become very bright if its lead compound, small molecule AGI-1067, passes through phase 3 trials for patients with atherosclerotic plaques. If the outcome of the trial is positive, the $50 million licensing bet that AstraZeneca made on AtheroGenics in December 2005 might prove to be a cheap gamble as AtheroGenics could otherwise have got almost $1 billion out of the deal.

Product development, Forecasts, trends, outlooks, Biotechnology industry, Biotechnology industries, Clinical trials, Industry forecasts

---

Niche indications could drive higher valuations

Article Abstract:

Gilead, a California based company is all set to purchase Colorado based Myogen which could demonstrate that companies with niche applications are becoming more attractive to better established biopharmaceutical companies. It is supposed that as a result of this, increased valuation for those niche biotech companies could follow.

Acquisitions & mergers, Mergers, acquisitions and divestments, Company acquisition/merger, Biological products industry, Gilead Sciences Inc., GILD

Similar abstracts:

• Abstracts: Production of a recombinant bacterial lipoprotein in higher plant chloroplasts. Regulating transgenic crops sensibly: Lessons from plant breeding, biotechnology and genomics
• Abstracts: Boeing makes money with Israeli missile partnership. Faster Boeing communications may boost net-centric operations
• Abstracts: Venture capital distributions: short-run and long-run reactions. What do entrepreneurs pay for venture capital affiliation?
• Abstracts: Impact of warrant introductions on the behavior of underlying stocks: Australian evidence. Coming stateside
• Abstracts: Budget shock sparks fears over trusts. When regulation causes more problems than solutions. Brown's tax gap crusade

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.